1-5 of 5
Haig H. Kazazian, Jr
Close
Sort by
Journal Articles

Successful Long Term Therapeutic Expression of Factor VIII in Hemophilia A Dogs After Administration of AAV-cFVIII Using a Two-Chain or Single Chain Delivery Approach.

Denise E. Sabatino, Ph.D., Ekaterina Altynova, B.S., Amy M. Lange, B.S., Shangzhen Zhou, M.D., Elizabeth P. Merricks, B.S., Aaron M. Dillow, B.S., Timothy C. Nichols, M.D., Valder R. Arruda, M.D., Ph.D., Haig H. Kazazian, Jr., M.D.
Journal: Blood
Blood (2009) 114 (22): 546.
https://doi.org/10.1182/blood.V114.22.546.546
Published: 2009
Journal Articles

Recombinant canine B-domain–deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model

Brief Report
Denise E. Sabatino, Christian Furlan Freguia, Raffaella Toso, Andrey Santos, Elizabeth P. Merricks, Haig H. Kazazian, Jr, Timothy C. Nichols, Rodney M. Camire, Valder R. Arruda
Journal: Blood
Blood (2009) 114 (20): 4562–4565.
https://doi.org/10.1182/blood-2009-05-220327
Published: 2009
Includes: Supplemental data
Journal Articles

Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype

Rita Sarkar, Renee Tetreault, Guangping Gao, Lili Wang, Peter Bell, Randy Chandler, James M. Wilson, Haig H. Kazazian, Jr
Journal: Blood
Blood (2004) 103 (4): 1253–1260.
https://doi.org/10.1182/blood-2003-08-2954
Published: 2004
Journal Articles

Correction of the coagulation defect in hemophilia A mice through factor VIII expression in skin

Steven S. Fakharzadeh, Yue Zhang, Rita Sarkar, Haig H. Kazazian, Jr
Journal: Blood
Blood (2000) 95 (9): 2799–2805.
https://doi.org/10.1182/blood.V95.9.2799.009k23_2799_2805
Published: 2000
Journal Articles

The Molecular Basis for Cross-Reacting Material–Positive Hemophilia A Due to Missense Mutations Within the A2-Domain of Factor VIII

Kagehiro Amano, Rita Sarkar, Susan Pemberton, Geoffrey Kemball-Cook, Haig H. Kazazian, Jr, Randal J. Kaufman
Journal: Blood
Blood (1998) 91 (2): 538–548.
https://doi.org/10.1182/blood.V91.2.538
Published: 1998